QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.068973v1 311/1/34    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lang, T. Articles by Zanger, U. M. Search for Related Content PubMed PubMed Citation Articles by Lang, T. Articles by Zanger, U. M.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles

Epidauros Biotechnologie AG, Am Neuland, Bernried, Germany (T.L., A.Z., R.K.); and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (K.K., T.R., M.E., M.S., U.M.Z.)

The human microsomal cytochrome P450, CYP2B6, is involved in the biotransformation of several clinically important drugs. By complete sequence analysis of the human CYP2B6 gene coding regions in selected Caucasian DNA samples, we identified the five novel missense mutations 62A>T (Q21L in exon 1), 136A>G (M46V in exon 1), 12820G>A (G99E in exon 2), 13076G>A (R140Q in exon 3), and 21388T>A (I391N in exon 8). The recently described but functionally uncharacterized variant 13072A>G (K139E) was also observed. Haplotype analysis indicated the presence of at least six novel alleles that code for the protein variants CYP2B6.10 (Q21L, R22C), CYP2B6.11 (M46V), CYP2B6.12 (G99E), CYP2B6.13 (K139E, Q172H, K262R), CYP2B6.14 (R140Q), and CYP2B6.15 (I391N). Heterologous expression in COS-1 cells revealed comparable levels of CYP2B6 apoprotein and bupropion hydroxylase activity for CYP2B6.1 (wild type) and CYP2B6.10, whereas all other variants exhibited reduced expression and/or function. The three amino acid changes M46V, G99E, and I391N resulted in almost unmeasurable (M46V) or undetectable (G99E and I391N) enzyme activity, despite the presence of residual protein. The K139E change led to completely abolished protein expression; as a consequence, no function was detected. Expression in insect cells by recombinant baculoviruses confirmed these results and demonstrated the virtual absence of incorporated heme in these protein variants. The collective allele frequency of the four very low or null activity variants M46V, G99E, K139E, and I391N was 2.6% in a Caucasian study population. These data provide further insight into the genetic variability of CYP2B6 and demonstrate the existence of phenotypic null alleles in this gene.

Address correspondence to: Dr. Ulrich M. Zanger, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany. E-mail: uli.zanger{at}ikp-stuttgart.de

This article has been cited by other articles:

				S. K. Bae, S. Cao, K.-A. Seo, H. Kim, M.-J. Kim, J.-H. Shon, K.-H. Liu, H.-H. Zhou, and J.-G. Shin Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes Drug Metab. Dispos., August 1, 2008; 36(8): 1679 - 1688. [Abstract] [Full Text] [PDF]

				N. Oezguen, S. Kumar, A. Hindupur, W. Braun, B. K. Muralidhara, and J. R. Halpert Identification and Analysis of Conserved Sequence Motifs in Cytochrome P450 Family 2: FUNCTIONAL AND STRUCTURAL ROLE OF A MOTIF 187RFDYKD192 IN CYP2B ENZYMES J. Biol. Chem., August 1, 2008; 283(31): 21808 - 21816. [Abstract] [Full Text] [PDF]

				C. Wyen, H. Hendra, M. Vogel, C. Hoffmann, H. Knechten, N. H. Brockmeyer, J. R. Bogner, J. Rockstroh, S. Esser, H. Jaeger, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients J. Antimicrob. Chemother., April 1, 2008; 61(4): 914 - 918. [Abstract] [Full Text] [PDF]

				M. H. Hofmann, J. K. Blievernicht, K. Klein, T. Saussele, E. Schaeffeler, M. Schwab, and U. M. Zanger Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 284 - 292. [Abstract] [Full Text] [PDF]

				S. Kumar, Y. Zhao, L. Sun, S. S. Negi, J. R. Halpert, and B. K. Muralidhara Rational Engineering of Human Cytochrome P450 2B6 for Enhanced Expression and Stability: Importance of a Leu264->Phe Substitution Mol. Pharmacol., November 1, 2007; 72(5): 1191 - 1199. [Abstract] [Full Text] [PDF]

				J. K. Blievernicht, E. Schaeffeler, K. Klein, M. Eichelbaum, M. Schwab, and U. M. Zanger MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms Clin. Chem., January 1, 2007; 53(1): 24 - 33. [Abstract] [Full Text] [PDF]

				J. Zukunft, T. Lang, T. Richter, K. I. Hirsch-Ernst, A. K. Nussler, K. Klein, M. Schwab, M. Eichelbaum, and U. M. Zanger A Natural CYP2B6 TATA Box Polymorphism (-82T-> C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site Mol. Pharmacol., May 1, 2005; 67(5): 1772 - 1782. [Abstract] [Full Text] [PDF]

				J.-Y. Cho, H.-S. Lim, J.-Y. Chung, K.-S. Yu, J.-R. Kim, S.-G. Shin, and I.-J. Jang HAPLOTYPE STRUCTURE AND ALLELE FREQUENCIES OF CYP2B6 IN A KOREAN POPULATION Drug Metab. Dispos., December 1, 2004; 32(12): 1341 - 1344. [Abstract] [Full Text] [PDF]